ライフサイエンスコーパス: SIV

1 SIV holders (SIVH) are applicants who were employed by,

2 SIV RNA expression was highest in the brainstem througho

3 SIV-infected animals showed decreased diversity of gut m

4 Compared to humans with HIV-1, SIV-infected NHPs had more hypermutated genomes, a relat

5 showed limited efficacy in preventing HIV-1/SIV acquisition in humans and macaques.

6 ched acutely (n = 4) or chronically (n = 12) SIV-infected rhesus macaques were analyzed by flow cytom

7 12 macaques remained uninfected following 15 SIV challenges.

8 Disease Notification system (EDN) for 19,167 SIV Iraqi and Afghan adults who resettled to the US from

9 nging task of nuclear translocation of HIV-2/SIV genome in nondividing target cells.

10 Viral protein X (Vpx) of HIV-2/SIV is known to be involved in the nuclear import of vir

11 SAMHD1, and is conserved among diverse HIV-2/SIV Vpx.

12 Here, we identified 7 SIV(mac239)-infected rhesus macaques (RMs), defined as P

13 Here, we identified 7 SIV-infected rhesus macaques that mirrored the human pos

14 ptides derived from the full proteomes of 82 SIV and simian HIV isolates.

15 s that distinguished vaccinees that acquired SIV infection from those that did not.

16 infant rhesus macaques to evaluate how acute SIV/SHIV infections impacted ILC3 and NK cells, which ar

17 Thus, acute SIV synaptic injury occurs throughout the brain, with sp

18 modulated following chronic, but not acute, SIV infection.

19 vage (BAL) following mucosal adenovirus (Ad)-SIV recombinant priming, intramuscular SIV envelope boos

20 sal priming with replicating adenovirus (Ad)-SIV recombinants, systemic boosting with SIV envelope pr

21 We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and a

22 adenovirus type 5 host range mutant (Ad5hr)-SIV recombinants and systemically boosted with ALVAC-SIV

23 n and at day 3, 7, or 14 after the 2nd Ad5hr-SIV prime and the 2nd vector/Env boost.

24 s of the lamina propria were destroyed after SIV infection and replaced by immature CD163(+)CD206(-)

25 ar macrophages are long-lived, survive after SIV infection, and may contribute to the virus reservoir

26 nts of CD8+ T cell-mediated efficacy against SIV.

27 d SIV vaccines significantly protect against SIV pathogenesis.

28 combination would enhance protection against SIV infection in rhesus macaques.

29 We engineered an ALVAC-SIV coexpressing CD40L with SIV(mac251) (ALVAC-SIV/CD40L

30 y in macaques with that of a canonical ALVAC-SIV, with both given as a vector-prime/gp120 in alum boo

31 V coexpressing CD40L with SIV(mac251) (ALVAC-SIV/CD40L) gag, pol, and env genes.

32 he ALVAC-SIV/CD40L was superior to the ALVAC-SIV regimen in inducing binding and tier 1 neutralizing

33 Unexpectedly, the ALVAC-SIV/CD40L vector had a blunting effect on CD4(+) Th1 hel

34 The ALVAC-SIV/CD40L was superior to the ALVAC-SIV regimen in induc

35 and boosted twice intramuscularly with ALVAC-SIV recombinant plus SIV gp120 protein or with DNA for S

36 mbinants and systemically boosted with ALVAC-SIV(M766)Gag/Pro/gp120-TM and SIV(M766&CG7V) gD-gp120 pr

37 Among SIV adults, 14.4% were diagnosed with latent tuberculosi

38 Among SIV children, 26.7% were susceptible to HBV infection, 2

39 ucosa, supporting their potential role as an SIV/HIV tissue reservoir.

40 An altered vaccine regimen containing an SIV Gag-FliC fusion antigen instead of Gag was significa

41 ircRNAome in rLCV-infected lymphomas from an SIV-infected rhesus macaque, and we report latent and ly

42 cterized specific neuronal populations in an SIV-infected macaque model with or without ART.

43 Several HIV-1 and SIV vaccine candidates have shown partial protection aga

44 ignificantly lower in uninfected animals and SIV-infected animals receiving ART.

45 parable levels of Env-binding antibodies and SIV-specific CD8(+) T-cells.

46 al and intact SIV-DNA in CD4(+) T cells, and SIV-DNA and SIV-RNA in B cell follicles, a major site of

47 t SIV-DNA in CD4(+) T cells, and SIV-DNA and SIV-RNA in B cell follicles, a major site of viral persi

48 ed that FIV evolves more slowly than HIV and SIV at the intra-individual level and found that mutatio

49 model reflects several hallmarks of HIV and SIV infection and latency.

50 AZD5582 results in the induction of HIV and SIV RNA expression in the blood and tissues of ART-suppr

51 and simian immunodeficiency viruses (HIV and SIV), irrespective of virus tropism, but not hepatitis C

52 ce and rhesus macaques infected with HIV and SIV, respectively.

53 ly lower than the rates recorded for HIV and SIV.

54 HIV- and SIV-envelope (Env) trimers are both extensively glycosyl

55 MAIT cells in serial samples from naive and SIV- or simian HIV-infected PTM.

56 hesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the inductio

57 the AP-2 complex with a simian tetherin and SIV Nef and determined its structure by cryoelectron mic

58 ted with ALVAC-SIV(M766)Gag/Pro/gp120-TM and SIV(M766&CG7V) gD-gp120 proteins formulated in alum hydr

59 lower levels of residual plasma viremia and SIV-DNA content in blood and tissues.

60 CD4 T cell counts, lower plasma viremia, and SIV-DNA content in blood and LN compared to NCs, but had

61 with CD8 T cells engineered to express anti-SIV T-cell receptor specificities enables direct experim

62 virologic features associated with post-ART SIV control in blood, lymph node (LN), and colorectal (R

63 Thus, increased cell-associated SIV DNA and RNA occurred in the HFD-receiving nonhuman p

64 PD-1, as well as amounts of cell-associated SIV DNA, SIV RNA, and replication-competent virus compar

65 ower plasma viremia, reduced cell-associated SIV-DNA, and preserved Th17 homeostasis, including at pr

66 After ATI, SIV-DNA content rapidly increased in NCs, while it remai

67 s differences in selected conditions between SIV children from Iraq and Afghanistan.

68 promote microbiome diversity compromised by SIV infection, improve the gut microbiota towards the he

69 reased binding of IgG to MUC16 after chronic SIV infection.

70 rhesus macaque IgG responses during chronic SIV infection generate increased antibodies that bind MU

71 show in an animal model of HIV that chronic SIV-infected gut contains innate lymphoid cells producin

72 In chronically SIV-infected animals, NKp44(+) ILCs negatively correlate

73 irect origin of viral rebound in chronically SIV-infected rhesus monkeys following ART discontinuatio

74 ound virus in 16 ART-suppressed, chronically SIV-infected rhesus monkeys following ART discontinuatio

75 utated genomes, a relative paucity of clonal SIV sequences, and a lower frequency of deleted genomes.

76 ncipal coordinates analysis (PCoA) clustered SIV-infected untreated animals away from healthy and tre

77 n the body can contain replication-competent SIV and contribute to rebound of the virus after treatme

78 higher frequencies of polyfunctional CXCR5+ SIV-specific CD8+ T cells in various lymphoid tissues an

79 nterestingly, MAPK/ERK-2 packaging defective SIV failed to promote the efficient nuclear import of vi

80 with near-full-genome sequencing, we defined SIV genetic integrity after 9 to 18 months of combinatio

81 ILC frequencies were associated with delayed SIV acquisition and decreased viremia.

82 Further, early T(FH)-dependent SIV-specific B cell responses were also correlated with

83 well as amounts of cell-associated SIV DNA, SIV RNA, and replication-competent virus comparable to t

84 /IL-17-producing ILCS was not altered during SIV infection.

85 blood lipopolysaccharide (LPS) levels during SIV infection were reduced to near normal upon ART, indi

86 y revert microbial dysbiosis observed during SIV and HIV infections.

87 reverted microbial dysbiosis observed during SIV infection.

88 None of the tested interventions enhanced SIV-specific CD8(+) T cell responses during ART or viral

89 virus (rAd) vectors that transiently express SIV internal proteins induced T cell responses that cont

90 kara (rMVA) booster vaccine, both expressing SIV antigens.

91 es intra-individual evolution rates for FIV, SIV, and HIV following systematic review of the literatu

92 T cells are significantly depleted following SIV infection, at levels that are similar to those measu

93 Vaccination with rAd vectors coding for SIV Gag or other nonenvelope proteins induces T cell res

94 inant plus SIV gp120 protein or with DNA for SIV genes and rhesus interleukin-12 plus SIV gp120 prote

95 n tissues are another cellular reservoir for SIV and may contribute to viral rebound after treatment

96 e used viably cryopreserved colon cells from SIV-infected and uninfected rhesus macaque monkeys and d

97 s are susceptible to pathologic changes from SIV infection, and intervention with ART did not fully a

98 g of the SIV antigen specificity of IgG from SIV-infected macaques revealed that the MUC16-eluted ant

99 his strategy failed to protect macaques from SIV acquisition.

100 estimate relevant biological parameters from SIV rebound data.

101 SIVmac239, vaccinees were not protected from SIV acquisition but manifested partial control of viremi

102 co-crystal structure of a fully glycosylated SIV(mac239)-gp120 core in complex with rhesus CD4 and th

103 Within the brainstem, the high SIV load and inflammation, along with reduction of HO-2,

104 Later treatment initiation led to higher SIV DNA levels maintained during treatment, which was si

105 he interplay between innate immunity and HIV/SIV is only poorly characterized.

106 alone, suppression of innate immunity by HIV/SIV is probably a key pathogenic determinant, making it

107 Thus, MAIT cells are of interest in HIV/SIV vaccination and infection.

108 ernable impact on the natural history of HIV/SIV infections and suggests that dietary changes can be

109 ervoir, since they harbor high levels of HIV/SIV, increase the pool of resting CD4(+) T cells by reve

110 ervoir, since they harbor high levels of HIV/SIV; reverse CD4(+) T cell immune activation status, inc

111 f morphine-altered antibody responses on HIV/SIV dynamics.

112 ion, with a potential negative impact on HIV/SIV pathogenesis.

113 s (Tregs) may be key contributors to the HIV/SIV latent reservoir, since they harbor high levels of H

114 ncy/virus simian immunodeficiency virus (HIV/SIV) infections.

115 ltration in the adipose tissue, an important SIV reservoir, and heightened systemic immune activation

116 To understand the role of IL-15 in SIV infection and pathogenesis, we treated two cohorts o

117 ecombinant human interleukin-15 (rhIL-15) in SIV-infected rhesus macaques (RM).

118 ed with sustained viral control after ATI in SIV-infected RMs.IMPORTANCE While effective, antiretrovi

119 y administration of anti-PD-L1 (Avelumab) in SIV-infected RM receiving combination antiretroviral the

120 SIV gag-specific (CM9(+)) CD8(+) T cells in SIV-infected macaques, yet CCR5(+)CD8(+) T cells are sig

121 , little is known about health conditions in SIV children.

122 mited information about health conditions in SIV populations to help guide US clinicians caring for S

123 ttle is known about the health conditions in SIV populations.

124 The fraction of persistent DNA in SIV-infected NHPs starting cART during acute or chronic

125 Despite the increase in SIV admissions to the US over recent years, little is kn

126 However, a 100-fold increase in SIV DNA in PBMCs was associated with only a 2-fold incre

127 attributed to a vaccine-induced increase in SIV target cells.

128 modulating recovery from synaptic injury in SIV infection and suggest their therapeutic targeting fo

129 4(+) T cell count, and CD4(+) T cell loss in SIV-infected macaques under conditioning with morphine.

130 cable and noncommunicable diseases (NCDs) in SIV adults to guide recommendations to clinicians in the

131 ing transcription factor 3 (regeneration) in SIV infection, which was significantly lower in uninfect

132 l to traffic to sites of viral reservoirs in SIV-infected rhesus macaques had no demonstrable effect

133 ot play a demonstrable, nonredundant role in SIV replication or CD4(+) T cell deletion dynamics but m

134 model, morphine plays a differential role in SIV reservoirs by reducing the CD4+ T-cell reservoir in

135 s after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and ro

136 intact proviral DNA levels, and in inducible SIV reservoir in lymph nodes (LNs) of morphine administe

137 dCA specifically inhibits SIV Tat binding to TAR, but not a Tat-Rev fusion protein

138 t PD-1 alone, decreased the total and intact SIV-DNA in CD4(+) T cells, and SIV-DNA and SIV-RNA in B

139 lly, we report an assay for measuring intact SIV genomes which may have value in cure research.

140 as a significantly higher fraction of intact SIV proviral genomes compared to ART-treated HIV-1 or HI

141 (Ad)-SIV recombinant priming, intramuscular SIV envelope boosting and infection following repeated l

142 Following repeated low-dose intrarectal SIV challenges, both vaccine groups exhibited modestly b

143 ion following repeated low-dose intravaginal SIV exposures.

144 nd subsequent repeated low-dose intravaginal SIV exposures.

145 GC maturation and generation of long-lasting SIV-specific humoral responses at mucosal and systemic s

146 ction to LNs, in the CNS, the size of latent SIV reservoirs was higher in the CD11b+ microglia/macrop

147 ntravaginal infection in a stringent macaque/SIV challenge model.

148 More SIV children were male (Iraqi 56.2%, Afghan 52.2%) and a

149 rly demonstrates direct effects of a mucosal SIV vaccine regimen on the rectal microbiome and validat

150 ection in Mamu-B*08(+) RMs following mucosal SIV challenges.

151 The vaccine regimen induced mucosal SIV-specific Ab, which mediated Ab-dependent cellular cy

152 licating adenovirus type 5 host range mutant SIV env/rev, gag, and nef recombinants and boosted twice

153 s outcome is achieved by comparing a natural SIV host, African green monkey (AGM) to an AIDS suscepti

154 to date have been unable to fully neutralize SIV(mac239).

155 d inducing T-cell responses against all nine SIV proteins.

156 9 genome capable of assembling noninfectious SIV particles and inducing T-cell responses against all

157 From our analysis, less than 1% of SIV children (Iraqi: 0.1%; Afghan: 0.12%) were reported

158 investigation, we found that less than 1% of SIV children were reported to have abnormal tuberculosis

159 In this analysis, we observed that 14% of SIV adults had LTBI, 27% of SIVH had at least one intest

160 bnormal tuberculosis test findings and 4% of SIV children had reported vision abnormalities.

161 K cell biology, especially in the context of SIV infection.IMPORTANCE Nonhuman primates play a crucia

162 icrobial translocation within the context of SIV/HIV infection.IMPORTANCE There is a slow yet signifi

163 C-I alleles associated with elite control of SIV infection.

164 gates in the somata of the frontal cortex of SIV-infected macaques.

165 S9 phosphorylation in the frontal cortex of SIV-infected macaques.

166 avaginally with repeated weekly low doses of SIV(mac251) administered 3 h after application of 0.8% S

167 d population size (cell death) in the DRG of SIV-infected animals compared with uninfected animals.

168 us (SIV) suggests that cytopathic effects of SIV resulting in chronic immune activation and dysregula

169 Instead, direct cytopathic effects of SIV resulting in chronic immune activation, along with t

170 te these effects, the kinetics and extent of SIV replication, CD4(+) T cell depletion, and the onset

171 In primary infection, reduced frequencies of SIV-specific effector T cells in an extralymphoid tissue

172 ly associated with an increased frequency of SIV reactivation and production of progeny capable of ca

173 t one intestinal parasite, and about half of SIV children had EBLL.

174 analyses could further explore the health of SIV children after resettlement in the US.

175 demonstrate that intravenous inoculation of SIV-infected macaques, a well-accepted non-human primate

176 s in blood and M s in the spleen and lung of SIV-infected ART-suppressed macaques.

177 A majority of SIV adults were male (Iraqi 54.0%, Afghan 58.6%) and age

178 ll depletion relative to other mechanisms of SIV-induced reactivation of LTBI, we used CD4R1 antibody

179 Using the nonhuman primate model of SIV infection in rhesus macaques, we investigated whethe

180 robiota, we used the rhesus macaque model of SIV infection to characterize and compare the gut microb

181 ines and cells from blood and lymph nodes of SIV infected macaques.

182 re studies can explore the health profile of SIV populations, including the prevalence of mental heal

183 The rate of SIV acquisition in the vaccinees was numerically lower (

184 BCG vaccination did not increase the rate of SIV oral transmission or disease progression.

185 ples, it did not reduce the relative risk of SIV-induced TB reactivation in ART-treated macaques in t

186 ffalo et al. describe a cryo-EM structure of SIV Nef complexed with AP-2 and tetherin.

187 otypic, functional, and phenotypic survey of SIV-specific CD8+ T cells across multiple anatomical sit

188 e first time we provide evidence that Vpx of SIV(smPBj1.9) physically interacts with human nucleopori

189 This structure explains the dependence of SIVs on tetherin DIWK and consequent barrier to human tr

190 bution, and organization partially depend on SIV and dystrophin.

191 In addition, CCR5 is highly expressed on SIV gag-specific (CM9(+)) CD8(+) T cells in SIV-infected

192 The HFD had a negative impact on SIV disease progression in both species.

193 iciency virus (SIV) but not in uninfected or SIV-infected antiretroviral therapy animals.

194 Overall, SIV vaccination influenced MAIT cell frequency and funct

195 -Retanef (RTN) vaccine controlled pathogenic SIV challenge despite high peak viremia.

196 on and subsequent protection from pathogenic SIV challenge.

197 kinetics similar to that seen in pathogenic SIV and HIV infection.

198 ciated with complete clearance of pathogenic SIV challenge virus, non-canonical major histocompatibil

199 The landscapes of persisting SIV, SHIV, and HIV-2 genomes are also dominated by defec

200 for SIV genes and rhesus interleukin-12 plus SIV gp120 protein.

201 nv/SIVGag/rhesus interleukin 12 (IL-12) plus SIV(M766&CG7V) gD-gp120 proteins formulated in alum phos

202 ramuscularly with ALVAC-SIV recombinant plus SIV gp120 protein or with DNA for SIV genes and rhesus i

203 ed, which were maintained even 12-weeks post-SIV infection.

204 D1 domain of the chimpanzee CD4 can prevent SIV cell entry.

205 Compared to previous SIV vaccine trials, the present DNA-MVA-VSV-Ad5-RRV-DNA

206 s and its microbiome in the nonhuman primate SIV model.

207 construct designed for eliminating proviral SIV DNA, leads to broad distribution of editing molecule

208 obiome and validates our previously reported SIV vaccine-induced sex bias.

209 lore other aspects of health among resettled SIV populations, including noncommunicable diseases and

210 cused on immunodominant Mamu-B*08-restricted SIV epitopes in Vif and Nef, and prophylactic vaccinatio

211 mmatory vaccine adjuvant may influence RhCMV/SIV vaccine immunogenicity and efficacy.

212 rt presents the first investigation of RhCMV/SIV vaccines in RhCMV-seronegative macaques lacking anti

213 ectored simian immunodeficiency virus (RhCMV/SIV) vaccines are associated with complete clearance of

214 anges have on oral and gut homeostasis, SHIV/SIV pathogenesis, and oral opportunistic disease.IMPORTA

215 Since SIV(MAC) lacking both Vpx and Vpr was less pathogenic th

216 initiation with DTG monotherapy, we started SIV-infected macaques on DTG during either acute or chro

217 Other partially successful SIV/HIV-1 protective vaccines induce antibody to the env

218 inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation.

219 simian immunodeficiency virus-coinfected (TB/SIV-coinfected) nonhuman primates.

220 ential model for systematic evaluation of TB/SIV coinfection and different treatment regimens and str

221 ng both Vpx and Vpr was less pathogenic than SIV deficient for Vpr or Vpx alone, suppression of innat

222 Our data revealed that SIV/SHIV infection led to a depletion of ILC3 and an inc

223 utralizing monoclonal antibodies against the SIV envelope glycoprotein that only block alpha(4)beta(7

224 d type 1 CD4(+) T cell responses against the SIV envelope protein and failed to protect macaques from

225 nerated a recombinant RRV that expresses the SIV Gag antigen and does not express gL.

226 is and heightened cardiovascular risk in the SIV-infected HFD-receiving nonhuman primates.

227 Testing of the SIV antigen specificity of IgG from SIV-infected macaque

228 ew insight into the size and location of the SIV reservoir could have great implications for HIV-infe

229 A large but transient boost of the SIV-specific CD8(+) T cell responses occurred in IL-2-DT

230 and elicited strong immune responses to the SIV Gag antigen.

231 loss of RNA polymerase II recruitment to the SIV promoter.

232 n that only block alpha(4)beta(7) binding to SIV Env but have no other host-directed effects.

233 ell-based assays, that dCA directly binds to SIV Tat's basic domain.

234 4(+) ILCs and Deltagamma cells contribute to SIV infection outcomes.

235 one of the first immune cells to respond to SIV infection.

236 PTM MAIT cells responded to SIV/simian HIV infection by proliferating and upregulati

237 deficiency virus-coinfected (M. tuberculosis/SIV-coinfected) macaques to model M. tuberculosis/HIV co

238 We investigated two SIV vaccine regimens combining mucosal priming immunizat

239 aca fascicularis, vaccinated with unmodified SIV gag alone in a DNA prime followed by an rAd boost ex

240 positions of gut microbiota communities upon SIV infection and at different time points of ART.

241 and compare the gut microbial community upon SIV infection and during ART.

242 apid anamnestic gp140 antibody response upon SIV encounter.

243 Using SIV-infected rhesus macaques, we analyzed multiple brain

244 nd to be evolutionarily conserved in various SIV isolates and HIV-2.

245 These findings confirm that RhCMV-vectored SIV vaccines significantly protect against SIV pathogene

246 s postinfection [dpi]) and quantified viral (SIV gag RNA), synaptic (PSD-95; synaptophysin), axonal (

247 1 (HIV-1) and simian immunodeficiency virus (SIV) acquisition in humans and macaques.

248 ntasomes from simian immunodeficiency virus (SIV) and HIV have clarified the INSTI binding modes with

249 Simian immunodeficiency virus (SIV) and human immunodeficiency virus 2 (HIV-2) display

250 a mixture of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV).

251 ural hosts of simian immunodeficiency virus (SIV) avoid AIDS despite lifelong infection.

252 infected with simian immunodeficiency virus (SIV) but not in uninfected or SIV-infected antiretrovira

253 undergo oral simian immunodeficiency virus (SIV) challenges 3 weeks later.

254 ry protein of simian immunodeficiency virus (SIV) engages the clathrin adaptor AP-2 to downregulate t

255 ally found in simian immunodeficiency virus (SIV) Env to improve rhesus CD4 binding.

256 3R expressing simian immunodeficiency virus (SIV) Gag and Pol and HIV envelope (SHIV) (MVA-B13R/SHIV)

257 etic swarm of simian immunodeficiency virus (SIV) in rhesus macaques to investigate the generation an

258 le control of simian immunodeficiency virus (SIV) in rhesus macaques.

259 Using the simian immunodeficiency virus (SIV) infection model, we show that combination antiretro

260 of latent HIV/simian immunodeficiency virus (SIV) infection of adult humans and rhesus macaques.

261 tems based on simian immunodeficiency virus (SIV) infection of macaques are available but do not reca

262 Simian immunodeficiency virus (SIV) infection of rhesus macaques (RhMs) is the best-cha

263 y virus (HIV)/simian immunodeficiency virus (SIV) infection, and blockade of this pathway may have po

264 r fate during simian immunodeficiency virus (SIV) infection, and their contribution to viral persiste

265 th or without Simian immunodeficiency virus (SIV) infection.

266 secondary to simian immunodeficiency virus (SIV) infection.

267 tal data from simian immunodeficiency virus (SIV) infections in control and morphine-addicted macaque

268 rse HIV-1 and simian immunodeficiency virus (SIV) isolates.

269 reverses HIV/simian immunodeficiency virus (SIV) latency.

270 MPORTANCE The simian immunodeficiency virus (SIV) macaque model represents the best animal model for

271 is of HIV and simian immunodeficiency virus (SIV) Nef proteins in the context of recent structural ad

272 ithin days in simian immunodeficiency virus (SIV) or human immunodeficiency virus (HIV) infection, an

273 er the entire simian immunodeficiency virus (SIV) proteome by serial vaccinations.

274 utant (Ad5hr)-simian immunodeficiency virus (SIV) recombinants and boosted twice intramuscularly with

275 The simian immunodeficiency virus (SIV) rhesus macaque model of HIV infection can be useful

276 culosis (Mtb)/simian immunodeficiency virus (SIV) suggests that cytopathic effects of SIV resulting i

277 ith wild-type Simian Immunodeficiency Virus (SIV) to those of CMs infected (vaccinated) with a replic

278 owing various simian immunodeficiency virus (SIV) vaccine regimens in rhesus macaques (RMs) has not b

279 port here, in simian immunodeficiency virus (SIV)+ rhesus macaques and patients diagnosed with HIV, b

280 virus (FIV), simian immunodeficiency virus (SIV), and human immunodeficiency virus (HIV).

281 antigens from simian immunodeficiency virus (SIV), the macaque model for HIV.

282 del, infusing simian immunodeficiency virus (SIV)-infected animals with CD8 T cells engineered to exp

283 In simian immunodeficiency virus (SIV)-infected Asian macaque models of human immunodefici

284 mphoma from a simian immunodeficiency virus (SIV)-infected rhesus macaque.

285 Using simian immunodeficiency virus (SIV)-infected, long-term antiretroviral therapy (ART)-tr

286 ne control of simian immunodeficiency virus (SIV).

287 infected with simian immunodeficiency virus (SIV).

288 sive study of simian immunodeficiency virus (SIV)/SHIV-infected infant rhesus macaques (RM) and track

289 as by some simian immunodeficiency viruses (SIVs) infecting wild chimpanzees, gorillas, or monkeys (

290 een 2,000 and 19,000 Special Immigrant Visa (SIV) holders (SIVH) from Iraq and Afghanistan resettle i

291 en 2,000 and 19,000 Special Immigrant Visas (SIV) annually, with the majority issued to applicants fr

292 In vitro, SIV/SHIV TILDA detects only cells expressing viral prote

293 ntibody levels in rectal secretions and with SIV-specific tissue resident memory B cells.

294 inated in the lamina propria in animals with SIV infection that were exhibiting AIDS.

295 y reversed the gut dysbiosis associated with SIV infection.

296 Ad)-SIV recombinants, systemic boosting with SIV envelope protein, and subsequent repeated low-dose i

297 ineered an ALVAC-SIV coexpressing CD40L with SIV(mac251) (ALVAC-SIV/CD40L) gag, pol, and env genes.

298 frequencies in blood and BAL correlated with SIV-specific antibody levels in rectal secretions and wi

299 owing chronic, but not acute, infection with SIV.

300 nef recombinants and boosted twice i.m. with SIV gp120 proteins in alum.